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Dallas and Arlington, TexasObjectives This study sought to evaluate the incidence, correlates, and clinical implications of
periprocedural myocardial injury (PMI) during percutaneous coronary intervention (PCI) of chronic
total occlusions (CTO).
Background The risk of PMI during CTO PCI may be underestimated because systematic cardiac
biomarker measurement was not performed in published studies.
Methods We retrospectively examined PMI among 325 consecutive CTO PCI performed at our
institution between 2005 and 2012. Creatine kinase-myocardial band fraction and troponin were
measured before PCI and 8 to 12 h and 18 to 24 h after PCI in all patients. PMI was deﬁned as creatine
kinase-myocardial band increase 3 the upper limit of normal. Major adverse cardiac events during
mid-term follow-up were evaluated.
Results Mean age was 64  8 years. The retrograde approach was used in 26.8% of all procedures.
The technical and procedural success was 77.8% and 76.6%, respectively. PMI occurred in 28 patients
(8.6%, 95% conﬁdence intervals: 5.8% to 12.2%), with symptomatic ischemia in 7 of those patients. The
incidence of PMI was higher in patients treated with the retrograde than the antegrade approach
(13.8% vs. 6.7%, p ¼ 0.04). During a median follow-up of 2.3 years, compared with patients without
PMI, those with PMI had a higher incidence of major adverse cardiac events (hazard ratio [HR]: 2.25,
p ¼ 0.006). Patients with only asymptomatic PMI also had a higher incidence of major adverse cardiac
events on follow-up (HR: 2.26, p ¼ 0.013).
Conclusions Systematic measurement of cardiac biomarkers post–CTO PCI demonstrates that PMI
occurs in 8.6% of patients, is more common with the retrograde approach, and is associated
with worse subsequent clinical outcomes during mid-term follow-up. (J Am Coll Cardiol Intv
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48Periprocedural myocardial injury (PMI) is a known com-
plication of percutaneous coronary intervention (PCI) and
has been associated with higher mortality, even when
patients do not develop symptoms or electrocardiographic
changes (1,2). PCI of chronic total occlusions (CTO) can be
technically challenging and may require the use of advanced
crossing techniques that could result in high rates of PMI
(3). In a weighted meta-analysis of 18,061 patients from 65
studies reporting complications after CTO PCI, the inci-
dence of PMI was 2.5% (95% conﬁdence interval [CI]: 1.9%
to 3.0%) and the incidence of Q-wave myocardial infarction
(MI) was 0.2% (95% CI: 0.1% to 0.3%) (4). However,
systematic cardiac biomarker measurements were not per-
formed in these studies; hence, the true incidence of PMI
may be underestimated. Furthermore, whereas in non-CTO
PCI PMI is associated with higher immediate and long-Abbreviations
and Acronyms
CABG = coronary artery
bypass graft
CI = conﬁdence interval(s)
CK-MB = creatine kinase-
myocardial band
CTO = chronic total
occlusion(s)
HR = hazard ratio(s)
IQR = interquartile range
MACE = major adverse
cardiac events
MI = myocardial infarction(s)
OR = odds ratio(s)
PCI = percutaneous coronary
intervention(s)
PMI = periprocedural
myocardial injury
ULN = upper limit of normalterm morbidity, the prognostic
implications of PMI in CTO
PCI remain unclear (4). To
overcome these limitations, we
performed the present study with
the following goals: 1) to evaluate
the incidence of both symptom-
atic and asymptomatic PMI in
CTO PCI using serial biomarker
measurements; 2) to assess the
association of PMI with various
CTO PCI techniques; and 3) to
determine the impact of PMI on
subsequent clinical outcomes.
Methods
Patients. BetweenMay 18, 2005,
and May 23, 2012, 325 consecu-
tive patients who underwent
CTO PCI at our institution had
their serial post-PCI cardiacbiomarker measurements determined (which is standard
policy at our institution for all PCI), and were included in the
present study. Their medical records, electrocardiograms, and
coronary angiograms were reviewed. The study was approved
by the institutional review board of our institution.
Deﬁnitions. Coronary CTOs were deﬁned as coronary
lesions with Thrombolysis In Myocardial Infarction ﬂow
grade 0 for a duration of at least 3 months. Estimation of the
occlusion duration was based on the ﬁrst onset of anginal
symptoms, previous history of MI in the target vessel
territory, or comparison with a previous angiogram.
Technical success of CTO PCI was deﬁned as successful
CTO revascularization with achievement of <30% residual
diameter stenosis within the treated segment and restora-
tion of Thrombolysis In Myocardial Infarction ﬂow grade
3 antegrade ﬂow. Procedural success was deﬁned asachievement of technical success with no in-hospital major
adverse cardiac events (MACE).
For in-hospital events, MACE was deﬁned as the
composite of death and clinical MI (symptoms or signs
suggestive of ischemia in addition to increase and fall of
cardiac biomarker levels). For events during follow-up,
MACE was deﬁned as the composite of all-cause death, MI
(deﬁned according to the universal deﬁnition of MI 2012
version), or any coronary revascularization (5).
All patients underwent creatine kinase-myocardial band
(CK-MB) and troponin measurement before PCI and at 8
to 12 and 18 to 24 h after PCI. PMI was deﬁned as CK-MB
increase 3 the upper limit of normal (ULN), if the
baseline CK-MB levels were below ULN. If the baseline
CK-MB levels were higher than the ULN, PMI was deﬁned
as a CK-MB increase 3 ULN if the relative increase of
the highest post-PCI CK-MB was >20% above the baseline
level. Periprocedural MI was deﬁned as the subset of PMI
patients who had evidence of prolonged ischemia as
demonstrated by persistent chest pain (>20 min), or new
pathological Q waves seen on the electrocardiogram (5).
Cardiac troponin level elevation was reported using various
cutoffs (3, 10, and 20 ULN). The ULN for
CK-MB and troponin at our institution was 6.3 ng/ml and
0.03 ng/ml, respectively.
Statistical analysis. Continuous variables were presented as
mean  SD or median with interquartile range (IQR) and
compared using the Student t test or Wilcoxon rank-sum test,
as appropriate. Categorical variables were reported as percent-
ages and compared using the chi-square or Fisher exact test, as
appropriate. A 2-sided p value of <0.05 was considered
statistically signiﬁcant. Logistic regression analysis was per-
formed to identify predictors of PMI in CTO PCI using the
SAS (SAS Institute, Cary, North Carolina) macro written by
Bursac et al. (6). Any variable having a signiﬁcant univariate
association with PMI (p 0.25) was selected as a candidate for
the multivariable analysis. Age, sex, diabetes, hypertension,
previous coronary artery bypass graft (CABG) surgery, use of
the retrograde approach, and procedure time were candidates
for the multivariable model. In the iterative process of variable
selection, covariates were removed from the model if they were
nonsigniﬁcant andnot confounders. Signiﬁcancewas evaluated
at the 0.1 alpha level and confounding as a change in any
parameter estimate>15%. At the end of this iterative process,
themodel contained signiﬁcant covariates and confounders. At
this point, any variable not selected for the original multivari-
able model was added back 1 at a time, with signiﬁcant cova-
riates and confounders retained earlier. Any that were
signiﬁcant at the 0.1 level were put in themodel, and themodel
was iteratively reduced as before, but only for the variables that
were additionally added.
The incidence of MACE was calculated using the
Kaplan-Meier method and compared using the log-rank
test, with hazard ratios (HR) calculated using Cox
Table 1. Clinical and Angiographic Characteristics and Outcomes of the Study Patients, Classiﬁed According
to Whether They Underwent CTO PCI Using the Antegrade or the Retrograde Approach
All Patients
(N ¼ 325)
Antegrade
(n ¼ 238)
Retrograde
(n ¼ 87) p Value
Age, yrs 64  8.4 64  8.8 64  7.4 0.704
Men 98.7 98.7 98.8 0.935
Hypertension 90.0 89.5 91.9 0.501
Hyperlipidemia 89.0 87.8 91.9 0.278
Diabetes 47.0 48.2 43.7 0.447
Heart failure 38.4 39.5 35.6 0.527
History of MI 47.3 45.4 53.9 0.231
History of CABG 26.0 20.7 40.2 0.001
History of stroke 4.3 3.8 5.7 0.452
Prior PCI 36.4 40.5 25.3 0.011
Initial presentation with ACS 20.9 23.5 13.8 0.048
CTO target vessel 0.001
RCA 56.2 47.0 79.1
LCX 20.9 25.6 9.3
LAD 21.6 26.1 10.5
LMCA/graft 1.3 1.4 1.3
Number of stents implanted 2 (0, 3) 2 (1, 3) 3 (0, 4) 0.387
Procedure time, min 124 (88–177) 107.5 (84.3–141.7) 192 (151–238) 0.001
Fluoroscopy time, min 34.7 (21.6–52.7) 28.6 (18.5–40.3) 55.2 (44.6–71.7) 0.001
Air kerma radiation exposure, Gy 4.4 (3.0–5.9) 3.4 (2.4–5.0) 5.7 (4.5–7.3) 0.001
Contrast volume, ml 338 (250–430) 310 (230–400) 400 (300–500) 0.001
Post-PCI CK-MB increase 3 ULN 8.6 6.7 13.8 0.044
Post-PCI Troponin 3 ULN 60.6 51.7 85.1 <0.0001
Post-PCI Troponin 10 ULN 43.1 33.2 70.1 <0.0001
Post-PCI Troponin 20 ULN 31.4 24.8 49.4 <0.0001
Technical success 77.8 80.7 70.1 0.047
Procedural success 76.6 80.3 66.7 0.014
Values are mean  SD, percentage, or median (interquartile range).
ACS ¼ acute coronary syndrome; CABG ¼ coronary artery bypass graft; CK-MB ¼ creatine kinase-myocardial band; CTO ¼ chronic total
occlusion; LAD ¼ left anterior descending; LCX¼ left circumﬂex; LM ¼ left main coronary artery; MI¼myocardial infarction; PCI ¼ percutaneous
coronary intervention; RCA ¼ right coronary artery; ULN ¼ upper limit of normal.
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49proportional hazard. Sensitivity and speciﬁcity of post-PCI
troponin values for the prediction of MACE were evaluated
with receiver-operating characteristic curves, and the You-
den index was calculated for each troponin cutoff value.
Statistical analyses were performed using JMP (version 9.0,Table 2. Clinical Presentation of Patients Who Underwent CTO PCI
During the Study Period
Clinical Presentation Number (N ¼ 325) Percentage of Total
Stable angina 257 79.1
Acute coronary syndrome 68 20.9
Unstable angina 31 9.5
NSTEMI 36 11.1
STEMI 1 0.31
NSTEMI ¼ non–ST-segment elevation myocardial infarction; STEMI ¼ ST-segment elevation
myocardial infarction; other abbreviations as in Table 1.SAS Institute), SAS (version 9.2 for Linux, SAS Institute),
and Stata (release 11, StataCorp, College Station, Texas).Results
Patient characteristics. The clinical and procedural charac-
teristics of the study patients are presented in Table 1. As is
common in CTO PCI series, most patients were men with
a high prevalence of atherosclerosis risk factors. Approxi-
mately 1 in 4 patients had previous CABG, and 1 in 3
patients had previous PCI. The most common CTO target
vessel was the right coronary artery. The retrograde approach
was used in 26.8% of procedures and the technical and
procedural success was 77.8% and 76.6%, respectively.
Procedure time, ﬂuoroscopy time, air kerma radiation
exposure, and total contrast utilization were higher in
patients treated with the retrograde approach (p ¼ 0.001).
Figure 1. Post-PCI Peak CK-MB Levels of the 28 Patients Who Developed PMI During CTO PCI
Periprocedural myocardial infarction (MI) occurred in 7 of the 28 patients with periprocedural myocardial injury (PMI): 6 patients had prolonged ischemic symptoms
>20 min, and 1 patient (Patient #7) had both prolonged chest pain and new Q-wave MI. CK-MB ¼ creatine kinase-myocardial band; CTO ¼ chronic total occlusion;
PCI ¼ percutaneous coronary intervention; ULN ¼ upper limit of normal.
Lo et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 1 , 2 0 1 4
PMI After CTO Interventions J A N U A R Y 2 0 1 4 : 4 7 – 5 4
50The clinical presentation of patients who underwent
CTO PCI is shown in Table 2. Approximately 80% of
patients presented with stable angina and 20% with recent
acute coronary syndrome, mainly non–ST-segment eleva-
tion acute myocardial infarction or unstable angina. More
patients presenting with acute coronary syndrome were
treated using the antegrade than the retrograde approach
(23.5% vs. 13.5%, p ¼ 0.048) (Table 1).
Frequency of periprocedural myocardial injury. PMI occurred
in 28 patients (8.6%; 95% CI: 5.8% to 12.2%). The mean and
median CK-MB levels were 69  73 and 39 (IQR: 22 to
103) ng/ml, respectively (Fig. 1). The baseline and maximum
CK-MB for these 28 patients are presented in Table 3. Of
the 325 CTO PCI patients studied, 30 had elevated baseline
CK-MB 6.3 ng/ml (ULN): 9 of these 30 patients had peak
post-PCI CK-MB 3 ULN, but 3 patients had peak post-
PCI CK-MB that were less than baseline CK-MB and thus
were not categorized as PMI. Therefore, 6 patients, or 21.4%
of patients with PMI, had baseline CK-MB ULN and still
met the criteria for PMI (Table 3).
Periprocedural MI occurred in 7 of the 28 patients with
PMI (25% of PMI patients or 2.1% of CTO PCI patients)
as 6 patients had prolonged ischemic symptoms >20 min,
and 1 patient (Patient #7) had both prolonged chest pain
and new Q-wave MI (Q-wave MI developed in 3.6% ofPMI patients or 0.3% of total CTO PCI patients) (Fig. 1).
The frequency of periprocedural cardiac troponin elevation
3, 10, and 20 ULN was 61%, 43%, and 31%,
respectively. Irrespective of the troponin cutoff used to
deﬁne PMI, the frequency of periprocedural troponin
elevation was greater when the retrograde approach was used
(p < 0.0001) (Table 1).
Correlates of periprocedural myocardial injury. The frequency
of PMI among 21 patients who had a procedural compli-
cation (e.g., emergency CABG, tamponade) was 19%
versus 8% among patients who did not have a complication
(p ¼ 0.12). PMI was numerically higher among patients in
whom CTO PCI failed compared with those in whom
CTO PCI was successful (11.8% vs. 7.6%, p ¼ 0.268).
The clinical characteristics and outcomes of patients with
PMI versus those without PMI are shown in Table 4.
Patients with PMI were more likely to have hypertension
and previous CABG (p ¼ 0.014). They were also more
likely to have had CTO PCI using the retrograde approach:
PMI occurred in 13.8% of patients in whom the retrograde
approach was used compared with 6.7% of patients in whom
only antegrade crossing was performed (p ¼ 0.044). Ante-
grade dissection/re-entry was used in 29% of cases and
antegrade wire escalation was used in 90.3% of cases. The
incidence of PMI when antegrade dissection/re-entry
Table 3. Baseline and Peak Post-PCI CK-MB Levels for All Patients
With PMI
Patient # Baseline CK-MB (ng/ml) Peak Post-PCI CK-MB (ng/ml)
1 6.9 22.5
2 1.9 99.1
3 1.1 106.1
4 1.9 112.8
5 6.6 40.9
6 2.4 223.8
7 12.3 341.7
8 4.1 19.5
9 1.7 21.7
10 5.0 23.8
11 3.0 24.5
12 3.3 25.8
13 2.6 41.7
14 6.2 45.6
15 7.2 54.7
16 2.1 79.6
17 1.2 80.0
18 2.5 137.0
19 24.9 143.3
20 1.1 24.1
21 6.8 34.0
22 4.3 36.0
23 2.9 36.4
24 1.3 39.1
25 1.8 52.5
26 3.0 75.9
27 5.6 104.3
28 1.0 136.9
PMI ¼ periprocedural myocardial injury; other abbreviations as in Table 1.
Table 4. Clinical and Angiographic Characteristics and Outcomes of the
Study Patients, Classiﬁed According to Whether They Had PMI
All Patients
(N ¼ 325)
PMI
(n ¼ 28)
No PMI
(n ¼ 297)
p
Value
Age, yrs 64  8.4 63  5.6 64  8.7 0.281
Men 98.7 100.0 98.6 0.394
Hypertension 90.0 100.0 89.2 0.014
Hyperlipidemia 89.0 92.9 88.6 0.464
Diabetes 47.0 32.1 48.5 0.094
Heart failure 38.4 35.7 38.7 0.754
History of MI 47.3 50.0 47.1 0.772
History of CABG 26.0 46.4 24.0 0.014
History of stroke 4.3 3.6 4.4 0.837
Prior PCI 36.4 46.4 35.5 0.256
Retrograde approach 26.8 43.9 25.3 0.044
CTO target vessel 0.393
RCA 56.2 73.1 54.6
LCX 20.9 15.4 21.5
LAD 21.6 11.5 22.6
LMCA/graft 1.3 0 1.5
Technical success 77.8 67.9 78.8 0.201
Procedural success 76.6 67.9 77.4 0.268
Number of
stents implanted
2 (0–3) 3 (0–4) 2 (0–3) 0.778
Procedure time, min 124 (88–177) 175 (147–241) 120 (88–174) <0.0001
Fluoroscopy
time, min
34.7 (21.6–52.7) 64.5 (43.5–72.7) 31.9 (21.1–50.0) <0.0001
Air kerma radiation
exposure, Gray
4.4 (3.0–5.9) 5.9 (5.3–7.4) 4.2 (2.8–5.6) 0.012
Contrast volume, ml 338 (250–430) 450 (375–545) 325 (245–415) <0.0001
Values are mean  SD, %, or median (interquartile range).
Abbreviations as in Tables 1 and 3.
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51crossing strategies were used was 11.2% versus 7.7% when
such strategies were not used (antegrade wire escalation and/
or retrograde approach, p ¼ 0.311). If retrograde CTO PCI
cases were excluded from the analysis, the PMI rate with
antegrade dissection/re-entry was similar to that of ante-
grade wire escalation (8% of 50 cases vs. 7% of 213 cases,
p ¼ 0.821). On multivariable analysis, results of the
purposeful selection model yielded 2 variables associated
with PMI: diabetes (adjusted odds ratio [OR]: 0.45; 95%
CI: 0.19 to 1.04; p ¼ 0.061) and previous CABG (adjusted
OR: 3.03; 95% CI: 1.36 to 6.75; p ¼ 0.007). The incidence
of PMI tended to increase over time in conjunction with an
increase in the use of retrograde crossing strategies and was
unrelated to the utilization of antegrade dissection/re-entry
strategies (Fig. 2).
PMI and clinical outcomes after CTO PCI. During mid-term
follow-up (median: 2.3 years; IQR: 0.8, 4.6 years), 40% of
patients experienced MACE: 11% died; 9% had an acute
coronary syndrome; 28.5% required PCI; and 3.4% under-
went CABG. The incidence of MACE during mid-term
follow-up was higher among patients who had PMI duringthe index PCI than in those who did not (HR: 2.25; 95%
CI: 1.28 to 3.70; p ¼ 0.006) (Fig. 3). When patients with
asymptomatic PMI were analyzed separately from those
with periprocedural MI, the incidence of MACE was still
higher among patients who had asymptomatic PMI
compared with those who had no PMI (HR: 2.26; 95% CI:
1.21 to 3.88; p ¼ 0.013) (Fig. 4). Patients with periproce-
dural MI had a trend toward a higher incidence of MACE
than did patients without PMI (HR: 2.23; 95% CI: 0.55 to
5.92; p ¼ 0.226) (Fig. 4). As shown in Table 5, patients
with asymptomatic PMI, periprocedural MI, and no PMI
were discharged on similar medication regimens.
Receiver-operating characteristic curves were used to
determine a threshold for post-PCI peak troponin associa-
tion with MACE (Fig. 5). The area under the curve for the
1-year incidence of MACE was 0.577 (95% CI: 0.506 to
0.647, p ¼ 0.034). The discriminatory capacity of troponin
for the 1-year incidence of MACE was similarly low among
patients undergoing antegrade (area under the curve: 0.579;
95% CI: 0.497 to 0.660, p ¼ 0.0649) or retrograde (area
under the curve: 0.588; 95% CI: 0.447 to 0.729, p ¼ 0.200)
CTO PCI. The optimal troponin value for 1-year incidence
Figure 2. Temporal Trends
Temporal trends in the incidence of PMI, use of the retrograde approach, and
use of the antegrade dissection/re-entry in CTO PCI. Abbreviations as in
Figure 1.
Figure 4. Incidence of MACE Among Study Patients, Classiﬁed According
to the Occurrence of PMI
Kaplan-Meier curves describing the incidence of MACE among patients with
asymptomatic PMI, symptomatic PMI, and no PMI. Abbreviations as in
Figures 1 and 3.
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52of MACE as deﬁned using the maximum Youden index was
1.64 ng/ml (approximately 50 ULN). This cutoff value
provided 26% sensitivity and 88% speciﬁcity for the
prediction of MACE and a positive likelihood ratio of 2.12
and negative likelihood ratio of 0.84, suggesting poor
discriminatory capacity.
Discussion
The main ﬁndings of our study that used systematic evalu-
ation of cardiac biomarkers after PCI are as follows: 1) PMI
occurs more commonly than previously reported after CTOFigure 3. Kaplan-Meier Curves of the Incidence of MACE in Patients With
and Without PMI After CTO PCI
The incidence of major adverse cardiac events (MACE) during a median of
2.3 years (interquartile range: 0.8 to 4.6 years) was higher among patients who
had PMI during CTO PCI than in those who did not have PMI (hazard ratio: 2.25;
95% conﬁdence interval: 1.28 to 3.70, p ¼ 0.006). Abbreviations as in Figure 1.PCI; 2) it is more frequent when the retrograde approach is
used; and 3) it is associated with worse subsequent clinical
outcomes.
Incidence and presentation of PMI after CTOPCI. A systematic
review and meta-analysis of 65 studies that reported
complications after CTO PCI found wide variability in the
incidence of post-PCI MI (from 0% to 19.4%); however, the
pooled estimate was low (2.8%; 95% CI: 1.5% to 4.1%). The
incidence of Q-wave MI was very low (0.2%; 95% CI: 0% to
0.9%) (4). However, a major limitation of previous studies is
that they did not perform systematic cardiac biomarker
measurements, as is true for most contemporary PCI
procedures in the United States (only 7% of patients had
cardiac biomarker measurement post-PCI in the National
Cardiovascular Data Registry) (7).
This limitation was addressed by our study, in which
cardiac biomarkers were measured twice during the ﬁrst 24 h
after PCI and revealed that the actual incidence of PMI was
approximately 3-fold higher (8.6%; 95% CI: 5.8% to 12.2%)
than was suggested by previous reports. However, the inci-
dence of Q-wave MI was 0.2%, suggesting that most PMI
occurring during CTO PCI may affect limited areas of
myocardium. Accordingly, 75% of all patients with PMI in
our series did not have any ischemic symptoms.
Correlates of PMI after CTO PCI. The retrograde approach
has revolutionized CTO PCI by enabling high success rates
even in patients with very complex coronary anatomies (8,9).
The retrograde approach entails insertion of a coronary
guidewire via a collateral vessel in the coronary vessel distal
to the distal cap followed either by retrograde true-to-true
lumen crossing or by using a dissection/re-entry strategy,
such as the controlled antegrade and retrograde tracking and
dissection or reverse controlled antegrade and retrograde
Table 5. Discharge Medications of Patients Undergoing CTO PCI During the Study Period
All Patients
(N ¼ 325)
Asymptomatic PMI
(n ¼ 21)
Periprocedural MI
(n ¼ 7)
No PMI or Periprocedural MI
(n ¼ 297)
p
Value
Beta-blocker 93.5 95.2 100 93.2 0.579
ACEI or ARB 79.3 66.7 71.4 80.3 0.325
Statin 96.9 100 100 88.2 0.398
Aspirin 98.8 100 100 98.6 0.694
Thienopyridine 90.1* 81.0 85.7 90.9 0.383
Values are %. *Thienopyridine was administered in 98.8% of successful CTO PCI procedures versus 61.3% of failed CTO PCI procedures.
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; other abbreviations as in Tables 1 and 3.
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53tracking technique (9). Previous studies had shown a trend
for higher PMI with the retrograde approach. In an analysis
of 1,983 lesions in 1,914 patients from the European registry
of CTO, the retrograde approach was used in 11.8% of cases
and a trend for higher frequency of post-PCI MI was
observed in patients undergoing retrograde CTO PCI (2.1%
vs. 1.0%, p ¼ 0.08) (10). In the meta-analysis of 65 studies
reporting on CTO PCI complications among 884 patients
undergoing CTO PCI of 886 lesions using a retrograde
approach, PMI occurred in 1.8% (95% CI: 1.5% to 4.1%)
(4). Major complications such as death, emergent CABG,
and stroke were rare, each occurring in 0.1% of patients.
In our study, the incidence of PMI was approximately
2-fold higher among patients treated using a retrograde
versus an antegrade approach (13.8% vs. 6.7%, p ¼ 0.044).
The higher incidence of PMI with the retrograde approachFigure 5. Peak Post-PCI Troponin Levels ROC Curve
Receiver-operating characteristic (ROC) curve of peak post-PCI troponin levels
for determining the 1-year incidence of MACE. Abbreviations as in Figures 1
and 3.may be because of injury of the myocardium along the
collateral vessel used for retrograde crossing or could be
related to the use of dissection strategies that could disrupt
small coronary artery side branches. In a recent report,
magnetic resonance imaging after retrograde CTO PCI via
a septal collateral demonstrated a new area of delayed
hyperenhancement in the septum, suggesting injury from
guidewire or other equipment passage (11). The higher
incidence of PMI with the retrograde approach may also be
related to higher lesion complexity, as in most cases, the
retrograde approach was used after antegrade crossing
failure. Accordingly, the prevalence of previous CABG was
twice as high among patients in whom the retrograde
approach was used (Table 1), and previous CABG is known
to be associated with higher rates of procedural failure (12).
Similarly, right coronary artery CTO, which are more
challenging to cross, were more likely to be approached
using the retrograde approach (Table 1).
Implications of periprocedural myocardial injury and infarction
after CTO PCI. Although cardiac biomarker elevation after
routine PCI has been associated with higher immediate
and long-term mortality, the clinical and therapeutic impli-
cations of CTO PCI PMI remain controversial (5). Our
study demonstrates a higher incidence of MACE during
a median follow-up of 2.3 years among CTO PCI patients
who developed PMI. Possible explanations include compro-
mise of distal collateral vessels from microembolization,
heightened inﬂammatory state post-PCI PMI, predisposition
to arrhythmias after infarction, and higher rates of index
CTO PCI failure (Table 4) (11,13,14). Moreover, PMI
patients may be at higher risk for subsequent adverse events
because of comorbidities or higher coronary lesion complexity.
Troponin release in CTO PCI. Our study shows that troponin
release is common after both antegrade and retrograde CTO
PCI. The threshold value of troponin above the ULN
whereby an adverse prognosis is evident is not well deﬁned
(5,15). Currently, guidelines suggest that troponin elevation
>5 ULN should be considered evidence of cardiac injury
or infarction, but this threshold was arbitrarily chosen (5). In
our population, post-CTO PCI troponin levels had limited
association with MACE. A high troponin threshold (50
ULN) provided the best association with 1-year MACE,
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54suggesting that further studies are needed for determining
a clinically useful troponin threshold.
Study limitations. Our study is limited by the retrospective
single-center design and relatively small number of patients;
however, it is the ﬁrst study of its kind to be reported. Our
sample size may not have accommodated a larger set of
predictors, thereby potentially limiting replication. However,
our ﬁnal model revealed only 2 signiﬁcant predictors and
therefore had adequate statistical power. As is typical in
veteran populations, most of the included patients were men,
although men constitute the majority of patients in most
CTO PCI series. Moreover, the study patients often had
previous CABG, previous MI, and previous PCI, suggesting
that this may be a higher-risk group than the general pop-
ulation. In the United States, the use of CK-MB is currently
declining and hence CK-MB may not be available for
clinical use at all institutions.
Conclusions
We found that PMI occurs in 8.6% of patients undergoing
CTO PCI, is more common with the retrograde approach,
and is associated with worse clinical outcomes during mid-
term follow-up. Studies to better assess the pathophysiology
of PMI in the CTO PCI setting, its implications, and
preventive and treatment measures are needed.
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